"With the addition of the Genome AnalyzerIIe, Illumina now offers the broadest range of sequencing instruments in the industry," said Jay Flatley, president and CEO of Illumina. "The Genome AnalyzerIIe is a particularly important addition to our portfolio as it will allow a wide range of labs and institutions with limited capital budgets to affordably add next-generation sequencing capabilities."
Illumina provides an extensive portfolio of sequencing instruments designed to meet a wide range of user and application requirements:
- Genome AnalyzerIIe- For researchers with limited capital budgets, the Genome AnalyzerIIe provides an affordable entry point into next-generation sequencing. At launch, the Genome AnalyzerIIe provides 20 Gb of output and 200 million paired-end reads along with the industry's simplest workflow and system operation.
- Genome AnalyzerIIx - The most widely adopted next-generation sequencing platform in the industry, the Genome AnalyzerIIx is ideally suited for researchers with medium to high output requirements. Currently generating in excess of 50 Gb of data per run, the Genome AnalyzerIIx is a proven and scalable platform offering application flexibility, ease of use, and low operating cost.
- HiSeq 2000 - Redefining the trajectory of sequencing, HiSeq 2000 offers the best solution for applications demanding the highest throughput and lowest operating costs. With up to 200 Gb of output and two billion paired-end reads, HiSeq provides unprecedented sequencing output and user experience.
- iScanSQ -- Capable of providing up to 20 Gb of output and 200 million paired-end reads, iScanSQ offers researchers the flexibility to access both sequencing and microarray processing on a single platform. It is expected to launch in Q2 2010.
The Genome AnalyzerIIe is expected to begin shipping in Q1 2010. For more information on the Genome AnalyzerIIe and the full line of Illumina sequencing instruments, please visit our website at http://www.illumina.com/systems.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected shipping dates for the Genome AnalyzerIIe and the iScanSQ. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in new product development and manufacturing and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors
Peter J. Fromen, 858-202-4507
Sr. Director, Investor Relations
pfromen@illumina.com
or
Media:
Wilson Grabill, 858-882-6822
Senior Manager, Public Relations
wgrabill@illumina.com
